drug · protein
insulin human
Marketedupdated 3mo agoby $MNKD MANNKIND CORP🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 5Protein drug with a maximum clinical stage of Approval (across all indications), with an approval for diabetes mellitus and type 2 diabetes mellitus and 46 investigational indications.
indications
investigational
Type 2 Diabetes
targets
Insulin receptor
all catalysts(14)
approval · 14
Jun 27, 2014
approval
$MNKD3.9000+1.30%
AFREZZA (INSULIN RECOMBINANT HUMAN) — FDA approval
insulin human
→
Mar 12, 2015
approval
$MNKD3.9000+1.30%
AFREZZA (INSULIN RECOMBINANT HUMAN) — FDA approval
insulin human
→
Apr 17, 2015
approval
$MNKD3.9000+1.30%
AFREZZA (INSULIN RECOMBINANT HUMAN) — FDA approval
insulin human
→
Apr 20, 2015
approval
$MNKD3.9000+1.30%
AFREZZA (INSULIN RECOMBINANT HUMAN) — FDA approval
insulin human
→
Jun 24, 2015
approval
$MNKD3.9000+1.30%
AFREZZA (INSULIN RECOMBINANT HUMAN) — FDA approval
insulin human
→
Jun 24, 2015
approval
$MNKD3.9000+1.30%
AFREZZA (INSULIN RECOMBINANT HUMAN) — FDA approval
insulin human
→
Sep 16, 2015
approval
$MNKD3.9000+1.30%
AFREZZA (INSULIN RECOMBINANT HUMAN) — FDA approval
insulin human
→
Feb 17, 2016
approval
$MNKD3.9000+1.30%
AFREZZA (INSULIN RECOMBINANT HUMAN) — FDA approval
insulin human
→
Apr 7, 2016
approval
$MNKD3.9000+1.30%
AFREZZA (INSULIN RECOMBINANT HUMAN) — FDA approval
insulin human
→
Sep 29, 2017
approval
$MNKD3.9000+1.30%
AFREZZA (INSULIN RECOMBINANT HUMAN) — FDA approval
insulin human
→
Apr 24, 2018
approval
$MNKD3.9000+1.30%
AFREZZA (INSULIN RECOMBINANT HUMAN) — FDA approval
insulin human
→
Oct 25, 2018
approval
$MNKD3.9000+1.30%
AFREZZA (INSULIN RECOMBINANT HUMAN) — FDA approval
insulin human
→
Feb 3, 2023
approval
$MNKD3.9000+1.30%
AFREZZA (INSULIN RECOMBINANT HUMAN) — FDA approval
insulin human
→
Jan 23, 2026
approval
$MNKD3.9000+1.30%
AFREZZA (INSULIN RECOMBINANT HUMAN) — FDA approval
insulin human
→
Trials studying insulin human
- phase3Afrezza® INHALE-1 Study in Pediatrics
- phase4Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes
- phase4INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes
- phase3Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients
- phase4Afrezza® Dosing Optimization Study
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 39m ago
Found something off?
comments(0)
5-min edit window · permanent after that